
ALS News Today Home | ALS News Today
Study highlights role of natural killer immune cell subsets in ALS Certain subsets of natural killer (NK) cells, a part of the immune system, were elevated in the blood of people with amyotrophic lateral sclerosis (ALS), where they showed altered gene activity and signaling patterns, a study found. One subset was associated with altered immune signaling, while another was linked…
Top 10 ALS news stories of 2024
Dec 30, 2024 · News stories about clinical trials testing potential treatments were among the top 10 most-read articles on ALS News Today in 2024.
News Archives – ALS News Today
MDA 2025: Cholesterol receptor ‘critical’ in sporadic ALS disease Signaling at the low-density lipoprotein receptor, known as LDLR, may be an important driver of neurodegeneration in sporadic amyotrophic lateral sclerosis (ALS), according to new preclinical research by U.S. scientists. In earlier work, the scientists discovered that mice injected with cerebrospinal fluid, or …
New method may serve as platform for creating cell therapies for ...
4 days ago · Scientists have developed a new method that can grow motor neurons from skin cells, which may serve as a platform for ALS cell therapies.
Study highlights role of natural killer immune cell subsets in ALS
3 days ago · Certain subsets of natural killer (NK) cells, a part of the immune system, were elevated in the blood of people with amyotrophic lateral sclerosis (ALS), where they showed altered gene activity and signaling patterns, a study found.
Number of ALS cases in US expected to climb 10% by 2030: Study
Jan 8, 2025 · The number of ALS cases in the U.S. is expected to increase by over 10% by 2030, as compared with 2022 prevalence rates, per new study data.
MDA 2025: Cholesterol receptor ‘critical’ in sporadic ALS disease
6 days ago · A cholesterol receptor protein called LDLR appears to be a key driver of neurotoxicity in sporadic ALS, per new research using a mouse model.
Health Canada set to consider early approval of PrimeC for ALS
5 days ago · Health Canada has invited Neurosense Therapeutics to discuss the potential for giving conditional approval to PrimeC in treating amyotrophic lateral sclerosis (ALS), according to a company filing with the U.S. Securities and Exchange Commission.
Alchemab, Lilly partner on antibody-based treatments for ALS
Jan 13, 2025 · An Alchemab-Eli Lilly partnership aims to identify new treatments for ALS based on antibodies from people with very slow disease progression.
15 nonprofits join to form new ALS group, ALS United
Feb 13, 2025 · Fifteen nonprofit organizations across the U.S. formed a new ALS group, ALS United, to better address the needs of people living with amyotrophic lateral sclerosis (ALS) and drive advances in research toward better treatment options or a cure.